Publications by authors named "M Kuther"
Purpose: The OVA-YOND study is the first prospective, non-interventional trial designed to evaluate trabectedin (1.1 mg/m) plus PLD (30 mg/m) in patients with platinum-sensitive recurrent ovarian cancer (ROC), given according to the marketing authorization in real-life clinical practice across Germany.
Methods: Eligible patients were adults with platinum-sensitive ROC, pretreated with ≥ 1 platinum-containing regimen/s.
Article Synopsis
- The study aimed to measure the number of SV40 large tumor antigen (large T) molecules on the surface of SV40-transformed cell lines using cytofluorimetric analysis.
- Five different SV40-transformed cell lines were stained with a specific monoclonal antibody, and fluorescence signals were measured to determine the quantity of large T molecules per cell.
- Results showed varying amounts of large T molecules per cell across the different cell lines, highlighting the effectiveness of this technique for quantifying viral antigen expression on cell membranes.
The process of covalent immunochemical linking of viable cell membranes with a Simian Virus 40 (SV40) tumor antigen-derived undecapeptide, K(698)PPTPPPEPET(708) (KT), is described. The principle applied was the reaction of the lysine residue, K 698, of the undecapeptide with the succinimidyl moiety of a heterobifunctional linker molecule, N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) or sulfosuccinimidyl(4-iodo-acetyl)aminobenzoate (sulfo-SIAB). Thereby, upon release of N-hydroxy-succinimide, the rest of the linker molecule reacts covalently with the epsilon-NH2 group of lysine.
View Article and Find Full Text PDF